Results of the Women's Health Initiative Memory Study which indicated an increased risk of Alzheimer's disease (AD) in women treated with hormone therapy (HT) led to a reevaluation of the benefits versus harm of hormone interventions. As part of this reevaluation, disparities between the beneficial outcomes of estrogen (E2, ET) and progesterone (P4) found in basic science analyses and the adverse outcomes of clinical trials were clear as were the disparities between the generally positive outcomes of ET and HT in observational studies versus the deleterious outcomes of clinical trials. The Progesterone in Brain Aging and Alzheimer's Disease Program Project is designed to address key elements hypothesized to underlie these disparities as well as addressing the paucity of knowledge regarding the neurobiology of progesterone (P4) action in brain regions required for cognition and vulnerable to age associated degenerative disease such as Alzheimer's. ? ? The over arching hypothesis of our program is that the ovarian steroid hormone progesterone promotes the brain's molecular, synaptic, cellular, and behavioral plasticity and reduces its vulnerability to the development of Alzheimer's disease (AD). Specifically, we hypothesize that progesterone has direct effects via activation of progesterone receptors in hippocampus and indirect effects via interaction with estrogen pathways. We further hypothesize that the reproductive endocrine status, duration of ovariprivation and presence of AD related pathology regulates the plasticity response to ovarian steroids. ? ? We have designed the Program Project to investigate P4 action at 7 levels of function from molecular to behavioral to exacerbation of AD-like pathology in vivo. Embedded in each proposal is an assessment of: (1) P4 receptor expression; (2) direct effect of P4 on neural plasticity; (3) clinically relevant progestins for their comparability to P4; (3) change in response to E2 and P4 with reproductive endocrine status, age or duration of ovariprivation and (4) E2 and P4 regulation of neural plasticity or inflammatory responses in a triple transgenic mouse model of Alzheimer's disease. ? ? Our long-term goals are three fold: (1) To establish a foundation of P4 neurobiology in brain regions required for cognitive function and vulnerable to Alzheimer's disease. (2) To develop rodent models of human perimenopause and menopause for both our investigations and those within the field of women's health. (3) To provide insights into the basis of disparities between basic science outcomes and clinical trial outcomes as well as the disparities between observational studies and clinical trials of HT and AD. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
1P01AG026572-01A1
Application #
7081976
Study Section
Special Emphasis Panel (ZAG1-ZIJ-2 (J3))
Program Officer
Wise, Bradley C
Project Start
2006-08-15
Project End
2011-05-31
Budget Start
2006-08-15
Budget End
2007-05-31
Support Year
1
Fiscal Year
2006
Total Cost
$1,569,557
Indirect Cost
Name
University of Southern California
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Geifman, Nophar; Kennedy, Richard E; Schneider, Lon S et al. (2018) Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. Alzheimers Res Ther 10:4
Walters, Michelle J; Sterling, Joanna; Quinn, Crystal et al. (2018) Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open 8:e023664
Mosconi, Lisa; Brinton, Roberta Diaz (2018) How would we combat menopause as an Alzheimer's risk factor? Expert Rev Neurother 18:689-691
Mosconi, Lisa; Walters, Michelle; Sterling, Joanna et al. (2018) Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area. BMJ Open 8:e019362
Moser, V Alexandra; Uchoa, Mariana F; Pike, Christian J (2018) TLR4 inhibitor TAK-242 attenuates the adverse neural effects of diet-induced obesity. J Neuroinflammation 15:306
Berkowitz, C L; Mosconi, L; Rahman, A et al. (2018) Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach. J Prev Alzheimers Dis 5:245-252
Gahm, Jin Kyu; Shi, Yonggang; Alzheimer’s Disease Neuroimaging Initiative (2018) Riemannian metric optimization on surfaces (RMOS) for intrinsic brain mapping in the Laplace-Beltrami embedding space. Med Image Anal 46:189-201
Riedel, Brandalyn C; Daianu, Madelaine; Ver Steeg, Greg et al. (2018) Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer's Disease in the Aging Brain. Front Aging Neurosci 10:390
Scheyer, O; Rahman, A; Hristov, H et al. (2018) Female Sex and Alzheimer's Risk: The Menopause Connection. J Prev Alzheimers Dis 5:225-230
Mosconi, Lisa; Berti, Valentina; Quinn, Crystal et al. (2017) Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology 89:1382-1390

Showing the most recent 10 out of 105 publications